×
Download 2025 Brochure

Welcome to OPT Congress:
Oligonucleotides & mRNA Therapeutics

OPT Congress is the premier event for scientists and executive directors involved in discovering and developing oligonucleotide and mRNA therapeutics. For 2025 we are delighted to expand our content and offer a conference program dedicated to emerging oligo modalities, sharing cutting-edge research and technologies used in designing new targeted therapies. 

Now in its 10th year, this unique event brings together leading chemists, biologists, toxicologists, CMC experts, regulatory specialists and technology providers to discuss advances in next-generation therapeutics. In addition to 2 days of inspiring keynotes, breakout discussions and 95+ scientific presentations, we deliver two in-depth short courses to further add to the learning opportunities. We look forward to welcoming you to our community focused event, offering robust and customizable programming tailored to your specific needs.

 

4 Conferences
95+ Speakers
300+ Attendees
150+ Unique Organizations
2 Pre Conference Short Courses

2025 Plenary Speakers

Anastasia Khvorova, PhD

Anastasia Khvorova, PhD
Professor, RNA Therapeutic Institute, University of Massachusetts Medical School

Eric Swayze, PhD

Eric Swayze, PhD
Executive Vice President, Research, Ionis Pharmaceuticals

Edward Kaye, MD

Edward Kaye, MD
CEO and Director, Stoke Therapeutics

Rubina Parmar, PhD

Rubina Parmar, PhD
Vice President, Chemistry & Delivery Sciences, Intellia Therapeutics

Our Executive Advisory Board

Mano Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Dmitry Samarsky, PhD
Former CTO, Sirnaomics

Chandra Vargeese, PhD
CTO & Head, Platform Discovery Sciences, Wave Life Sciences

Arthur Levin, PhD
Executive Vice President, Research and Development, Avidity Biosciences

Lubo Nechev, PhD
Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals

Ekkehard Leberer, PhD
Senior Life Sciences Consultant, ELBIOCON